Strategies for improving the functionality of an affinity bioreactor.

Area of Science:

• Biomedical Engineering
• Materials Science
• Cardiovascular Surgery

Background:

• Heparin in extracorporeal blood circulation (ECBC) causes bleeding; protamine neutralization causes adverse reactions.
• Existing protamine bioreactors have unstable linkages and low heparin removal capacity.
• Clinical application requires overcoming protamine leaching and improving heparin adsorption efficiency.

Purpose of the Study:

• To develop a stable and highly efficient protamine bioreactor for ECBC.
• To address limitations of previous protamine immobilization and heparin adsorption methods.
• To enhance safety and efficacy in preventing bleeding and protamine-related adverse effects.

Main Methods:

• Developed a novel conjugation method using 4-(oxyacetyl)phenoxyacetic acid (OAPA) for stable protamine immobilization.
• Introduced multi-layer immobilization using poly-lysine to increase protamine density.
• Incorporated poly(ethylene glycol) (PEG) linkers for improved protamine accessibility and dynamic motion.

Main Results:

• OAPA method demonstrated virtually no protamine leaching compared to 35% with CNBr method.
• Immobilized protamine amount was comparable between OAPA and CNBr methods (7.45 mg/g vs. 7.69 mg/g).
• New strategies achieved a four- to five-fold enhancement in heparin adsorption capacity.

Conclusions:

• Novel strategies significantly improve protamine bioreactor stability and heparin removal efficiency.
• OAPA conjugation and multi-layer immobilization overcome key limitations for clinical use.
• These approaches offer a versatile platform for enhancing affinity bioreactor functionality, including for ITP treatment.